Navigation Links
K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
Date:5/25/2012

(a)  the risk that the maturities of our debt obligations may be accelerated due to our inability to comply with covenants and restrictions contained in our loan agreements;

(b)  restrictions on the ability to increase our revenues through certain transactions, including the acquisition or in-licensing of products; and

(c)   risks that future changes in the Board of Directors may lead to an acceleration of the maturities of the Company's debt;

(9)    the risk that we may not be able to satisfy the quantitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float; and

(10)  the risks detailed from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

Because the factors referred to above, as well as the statements included in Part I, Item 1A—"Risk Factors," of our Annual Report on Form 10-K/A for the fiscal year ended March 31, 2011, and Part II, Item 1A—"Risk Factors," and Part I, Item 2—"Management's Discussion and Analysis of Financial Condition and Results of Operations"  of our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2011, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to us are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included under Part I, Item 1A of the Fiscal 2011 Form 10-K/A for the fiscal year ended March 31, 2011, and Part II, Ite
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  Lakeland Industries, Inc. (NASDAQ: ... protective clothing for industry, municipalities, healthcare and first ... today announced that the Company accepted a commitment ... Facility subject to certain terms and conditions and ... no assurances can be given that this transaction ...
(Date:5/21/2013)... 21, 2013  Tom Daulton, CEO of Mammotome, a division ... Year by the Cincinnati chapter of ... by another local top executive who is also a breast ... Ethicon Endo-Surgery in March of 2010. Daulton will be presented ... presented by Huntington Bank, on May 22. The ...
(Date:5/21/2013)... Kepner-Tregoe (KT), the global capability development ... Chris Geraghty has been ... than 20 years serving the industrial sector, holding ... succeeds Ray Baxter , who ... the Board and CEO. (Logo: ...
Breaking Medicine Technology:Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 2Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 3Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 4Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 5Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 6Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 7Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 8Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 9Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 10Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 11Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 12Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 13Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3
... 14, 2011 /PRNewswire / -- Nephros, Inc. (OTC Bulletin Board: ... three months ended September 30, 2011. Recent ... associated with Rights Offering to be exercised; Received initial ... Hemodiafiltration System in U.S. Financial ...
... 14, 2011 Landauer, Inc. (NYSE: LDR ... radiation monitoring and the leading domestic provider of outsourced ... all of the outstanding equity interests of  IZI Medical ... a purchase price of approximately $93 million. IZI Medical ...
Cached Medicine Technology:Nephros Reports Third Quarter 2011 Financial Results 2Nephros Reports Third Quarter 2011 Financial Results 3Nephros Reports Third Quarter 2011 Financial Results 4Nephros Reports Third Quarter 2011 Financial Results 5Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 2Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 3Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 4Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 5Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC 6
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 DISCcert ... materials showing how to use 17 DISC applications at ... is a natural progression. , The July 25 & ... the top 17 ways of applying DISC. The time-tested, ... certified graduates. The user-friendly DISC training materials ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... The Orsiro stent, which is a novel stent ... non-inferiority to the Xience Prime everolimus-eluting stent for ... loss at nine months in the results of ... , The BIOFLOW-II substudy used intravascular ultrasound (IVUS) ... neointimal hyperplasia and stent apposition at nine months ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
... The Lancet Supports Cardio-Protective Potential of Aleglitazar - , ... will start Phase III clinical investigations for aleglitazar, its innovative ... morbidity and mortality in high risk patients with type 2 ... II SYNCHRONY study published today in The Lancet(1) ...
... , Customizable Survival Kit Offers One Stop for ... Local Healthcare Market Drivers and Health Plan Trends ... a leading provider of managed care market intelligence, ... shifts in membership at the state level than ...
... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...
... United Spinal Association ( www.UnitedSpinal.org ) presents the ... ) , the region,s premiere lifestyle-enhancing Expo designed to ... aging Americans. , , The Independence Expo will ... at the Suffolk Community College Sports & Exhibition Complex in ...
... PSI-7851 was generally safe and well tolerated in Phase 1a ... results from single ascending and multiple ascending dose trials are ... June 9 Pharmasset, Inc. (Nasdaq: VRUS ) ... study and begun dosing in a multiple ascending dose trial ...
... ... its Multilayer Aneurysm Repair System (MARS) has received CE Mark approval for treating patients ... ... announced today that it has received CE Mark approval for the commercial sale of ...
Cached Medicine News:Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 2Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 3Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 4Health News:Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack 5Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4Health News:Cardiatis Multilayer Aneurysm Repair System, MARS, Receives CE Mark Approval for Treating Peripheral Aneurysms 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: